NCT07140393 - A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2028

Conditions

Solid Tumor

Interventions

DRUG

HRS-4508+ Capecitabine

DRUG

HRS-4508+ Trastuzumab

DRUG

HRS-4508+ Trastuzumab+ Pertuzumab

DRUG

HRS-4508+ Trastuzumab+ Capecitabine

DRUG

Trastuzumab+ Capecitabine

DRUG

HRS-4508+A1811

Trial Locations (1)

Cancer Hospital Chinese Academy of Medical Science, Beijing

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY